{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-062072","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.883307+00:00","generated_at":"2026-06-18T09:17:57.647741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Alaunos reports Q4 2022 net loss $9.2M, cash $53M; TCR library expanded","bullets":["Net loss $9.2M in Q4 2022 ($0.04/share) vs $11.8M ($0.05) prior year; full year loss $37.7M.","Cash and restricted cash $53.0M; expects to fund operations into Q4 2023.","Expanded TCR library with two new TCRs, doubling potential addressable market; improving patient match rate from 5% to 10%.","Transitioned to cryopreserved cell product, reducing manufacturing time from 30 to 26 days (13% decrease).","Phase 2 readiness targeted in 2023; interim data on multiple patients expected mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-062072","json":"https://secwatch.observer/filing/0001193125-23-062072.json","markdown":"https://secwatch.observer/filing/0001193125-23-062072.md","text":"https://secwatch.observer/filing/0001193125-23-062072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523062072/0001193125-23-062072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523062072/d457628d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:17:57.647741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d50b91636daf1b6b70135c80bdbac0e1991d701","claim":"Alaunos Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 7, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing its fourth quarter and full year 2022 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523062072/0001193125-23-062072-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}